Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service DBS & VNS cases in Oregon: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (100 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 206 | 50% |
| 2020 | 2 | 132 | 51% |
| 2021 | 3 | 169 | 53% |
| 2022 | 2 | 177 | 56% |
| 2023 | 3 | 157 | 58% |
| 2024 | 2 | 121 | 59% |
| 2025 from claims | – | 127 104–150 | 59% |
| 2026 forecast | – | 130 103–165 | 58% |
| 2027 forecast | – | 132 99–176 | 58% |
| 2028 forecast | – | 133 96–185 | 58% |
| 2029 forecast | – | 134 93–195 | 58% |
| 2030 forecast | – | 135 91–204 | 58% |
Deep brain and vagus nerve stimulator implants. Professional codes (what the surgeon bills): CPT 61863, 61867, 61885, 61886, 64568; the hospital bills MS-DRG 040, 041, 042.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Oregon; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 57% inpatient hospital, 43% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 18 | 1,048−1.7%/yr | −1.7%/yr | 0.3 | 0% | 1,100 in 2030+0.8%/yr |
| Washington | 6 | 341−1.4%/yr | −1.4%/yr | 0.4 | 0% | 280 in 2030−3.1%/yr |
| Arizona | 4 | 296−8.8%/yr | −8.8%/yr | 0.4 | 0% | 520 in 2030+9.8%/yr |
| Colorado | 5 | 247−4.2%/yr | −4.2%/yr | 0.5 | 14% | 450 in 2030+10%/yr |
| Montana | 1 | 130−1.6%/yr | −1.6%/yr | 0.7 | 0% | 140 in 2030+1.3%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Stroke thrombectomy | 1 | 130−4.5%/yr | −4.5%/yr | 0.30.8× | 0% | 270 in 2030+13%/yr |
| Aneurysm & intracranial embolization | 2 | 108+11%/yr | +11%/yr | 0.30.5× | 0% | 150 in 2030+5.8%/yr |
DBS & VNS in every state, and its device makers · Every procedure market in Oregon · Every state · Compare with California
Boston Scientific leads with 62% of company spending on these surgeons in 2025, +6 pts on 2024.
In 2025, 5 companies reported engagement with Oregon’s surgeons worth $75K in consulting, speaking, meals and travel tied to these products, about $38K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 56 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.